Authors: Maublant, J Lumbroso, J Cachin, F Raoul, JL Syrota, A Vuillez, JP

Citation: J. Maublant et al., Nuclear medicine in oncology: New diagnostic and therapeutic methods, B CANCER, 88(1), 2001, pp. 35-44

Authors: Moins, N Cayre, A Chevillard, S Maublant, J Verrelle, P Finat-Duclos, F

Citation: N. Moins et al., Effects of MDR reversing agent combinations on the H-3-daunomycin accumulation in drug-sensitive and drug-resistant human cancer cells, ANTICANC R, 20(4), 2000, pp. 2617-2623

Authors: Cayre, A Moins, N Finat-Duclos, F Maublant, J Verrelle, P

Citation: A. Cayre et al., Comparative Tc-99m-sestamibi and H-3-daunomycin uptake in human carcinoma cells: Relation to the MDR phenotype and effects of reversing agents, J NUCL MED, 40(4), 1999, pp. 672-676

Authors: Maublant, J Resche, I Giammarile, F Corone, C Artus, JC

Citation: J. Maublant et al., News on nuclear oncology, B CANCER, 86(1), 1999, pp. 57-64

Authors: Camilleri, L Moins, N Mouchoniere, M Renoux, M Bailly, P Veyre, A Maublant, J de Riberolles, C

Citation: L. Camilleri et al., Cultured neonatal rat cardiomyocytes and Tc-99m-sestamibi to assess the direct effects of cardioplegia, CARDIOV SUR, 6(6), 1998, pp. 614-621

Authors: Maublant, J Vuillez, JP Talbot, JN Lumbroso, J Muratet, JP Herry, JY Artus, JC

Citation: J. Maublant et al., Positron emission tomography (PET) and [F-18]-fluorodeoxyglucose (FDG) in cancerology, B CANCER, 85(11), 1998, pp. 935-950